Emisphere Technologies and Savient Pharmaceuticals Show Impressive Growth
The Paragon Report Provides Equity Research on Emisphere Technologies & Savient Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 11/16/11 -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Emisphere Technologies, Inc. (OTCBB: EMIS) and Savient Pharmaceuticals, Inc. (NASDAQ: SVNT). Access to the full company reports can be found at:
While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Krystexxa was approved in September 2010 as a treatment for gout in patients that have not responded to standard treatments, or for patients who can't take certain drugs.
Emisphere Technologies, Inc., a biopharmaceutical company, focuses on a delivery of therapeutic molecules or nutritional supplements using its Eligen technology primarily in the United States. Under a co-development collaboration with Nordic Bioscience A/S, Novartis is using our Eligen drug delivery technology in combination with salmon calcitonin to treat osteoarthritis and osteoporosis.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.11.2011 - 13:16 Uhr
Sprache: Deutsch
News-ID 88466
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 233 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Emisphere Technologies and Savient Pharmaceuticals Show Impressive Growth"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
